{"filings":[{"id":1259121,"accession_number":"0001493152-26-030033","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2026-06-25T12:00:40+00:00","items":["7.01","9.01"],"status":"ready","headline":"MIRA Pharma reports preclinical data showing Mira-55 differentiated from THC, anxiolytic effect","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mira-55 did not produce THC-like locomotor suppression or catalepsy in standard preclinical assays.","Modest body temperature reduction from Mira-55 was not reversed by CB1 antagonist rimonabant, indicating distinct mechanism.","Mira-55 demonstrated anxiolytic activity, in contrast to anxiogenic activity of rimonabant; THC showed no anxiolysis.","Data builds on March 2026 results; company advancing Mira-55 toward IND for chronic inflammatory pain.","No psychoactivity or CNS side effects observed; candidate designed to avoid THC liabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1093521,"accession_number":"0001493152-26-028992","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2026-06-17T12:00:39+00:00","items":["7.01","9.01"],"status":"ready","headline":"MIRA submits Phase 2a protocol to FDA for Ketamir-2 in CIPN","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Phase 2a protocol (Mira-002) for oral NMDA receptor modulator Ketamir-2 in chemotherapy-induced peripheral neuropathy.","Randomized, double-blind, placebo-controlled, three-period crossover trial with 300 mg and 600 mg doses.","No FDA-approved therapies exist for CIPN; study targets 30–40% of chemo patients affected.","Phase 1 showed clean safety: no serious AEs or dose-limiting toxicities in 56 volunteers.","Trial to run at a leading U.S. cancer center; FDA acknowledged receipt of submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":920278,"accession_number":"0001493152-26-027751","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2026-06-08T21:00:43+00:00","items":["5.02","9.01"],"status":"ready","headline":"Mira Pharmaceuticals appoints fractional CFO after CFO Weichselbaum departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alan Weichselbaum resigned as CFO effective June 6, 2026, with no disagreement with the company.","Andriy Mushak, CPA with over 20 years SEC experience, appointed fractional CFO effective June 6, 2026.","Mushak will serve via consulting agreement with LMAM Consulting Group; company to pay $6,000 per month.","Mushak's expertise includes SEC reporting, audit readiness, internal controls, and capital-markets support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":843401,"accession_number":"0001493152-26-027202","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2026-06-04T12:00:41+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"MIRA secures worldwide exclusive rights to MIRA-55 and SKNY-1 via amended license","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended license with MIRALOGX LLC grants MIRA global exclusive rights to develop, commercialize, sublicense, and enforce IP for MIRA-55 and SKNY-1.","Core economic terms from prior license arrangements remain materially unchanged; no upfront or milestone payments disclosed.","MIRA CEO says the company now controls worldwide rights across entire pipeline: Ketamir-2, MIRA-55, and SKNY-1.","MIRA-55 targets chronic inflammatory pain; SKNY-1 targets obesity and addiction-related disorders—both investigational.","Agreement consolidates IP portfolio and enhances flexibility for future licensing and partnership opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":677758,"accession_number":"0001493152-26-025335","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2026-05-27T12:00:25+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"MIRA secures worldwide rights for Ketamir-2, expands IP to 10 markets ahead of Phase 2a","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment expands licensed territory from US, Canada, Mexico to all countries with patent rights.","IP portfolio now covers filings in 10 markets: US, Europe, China, Japan, Canada, Australia, India, Israel, Mexico, S. Korea.","Core economic terms (royalties, financial consideration) of original license agreement unchanged.","Company advancing Phase 2a protocol for FDA submission after positive Phase 1 data in 56 volunteers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":67802,"accession_number":"0001493152-26-022704","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2026-05-13T20:01:30+00:00","items":["7.01"],"status":"ready","headline":"Mira Pharmaceuticals announces positive Phase 1 results for Ketamir-2; plans Phase 2a in CIPN","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial in 57 healthy volunteers; all completed with no withdrawals or serious adverse events.","Ketamir-2 half-life 2.5–7 hours; active metabolite nor-Ketamir-2 half-life 7–9 hours; supports once-daily dosing.","DEA classified Ketamir-2 as not a controlled substance, eliminating scheduling barriers.","Company preparing Phase 2a protocol for chemotherapy-induced peripheral neuropathy (CIPN) for FDA submission.","Preclinical data showed Ketamir-2 superior efficacy vs. ketamine, pregabalin, and gabapentin in neuropathic pain models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":50166,"accession_number":"0001493152-26-022608","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2026-05-13T11:30:40+00:00","items":["8.01"],"status":"ready","headline":"MIRA Pharmaceuticals Publishes Peer-Reviewed Manuscript on SKNY-1 Preclinical Data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Manuscript titled 'SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors' published in International Journal of Molecular Sciences.","SKNY-1 oral administration produced approximately 30% reduction in body weight from baseline after six days in the higher-dose group.","SKNY-1 demonstrated differential CB1 signaling, partial CB2 agonist activity, and selective MAO-B inhibition relative to MAO-A.","Preclinical findings included normalization of total cholesterol and LDL, increased HDL, reduced hepatic triglycerides, and attenuated compulsive feeding and nicotine-seeking behaviors.","SKNY-1 has not been approved by the FDA; safety and efficacy not yet established in humans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110787,"accession_number":"0001493152-26-012085","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mira-55 shows no cannabinoid-like CNS side effects in preclinical studies; advancing toward IND for inflammatory pain","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mira-55 tested at 10, 30, and 100 mg/kg in CNS assays; no psychogenic, motor, or anxiogenic effects observed.","No catalepsy or sedation; dose-dependent increase in time spent in open arms of Elevated Plus Maze (anxiety reduction).","Rimonabant (positive control) showed anxiety-like behavior, validating assay sensitivity.","Prior data demonstrated Mira-55 produced morphine-comparable analgesia in inflammatory pain model without opioid risks.","Company plans IND submission for inflammatory pain; additional preclinical studies ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110786,"accession_number":"0001493152-26-008707","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA completes Phase 1 dosing of Ketamir-2; no serious AEs; plans Phase 2a in CIPN","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed Phase 1 study in 56 healthy volunteers; no serious adverse events or dose-limiting toxicities.","No clinically significant dissociative or psychotomimetic effects typically seen with ketamine observed.","Plans to submit Phase 2a proof-of-concept study to FDA in H1 2026 for chemotherapy-induced peripheral neuropathy (CIPN).","CIPN lacks FDA-approved therapies; Ketamir-2 is a selective oral NMDA receptor modulator."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110785,"accession_number":"0001493152-26-004739","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA Pharma initiates final cohort of Ketamir-2 Phase 1 MAD trial; 50 volunteers dosed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 MAD trial final cohort dosing underway; 50 healthy volunteers dosed, 6 remaining; completion expected by Q1 2026.","Phase 2a proof-of-concept study for CIPN planned; protocol submission to FDA after Phase 1; targeting Q2 2026 start.","Plans to pursue FDA Fast Track designation for Ketamir-2; to present Phase 1 data at AACR April 2026.","Preclinical programs SKNY-1 (weight loss/nicotine addiction) and MIRA-55 (inflammatory pain) advancing toward IND-enabling by year-end 2026.","Engaging in partnering discussions at BIO Partnering Investment & Growth Summit in March 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127411,"accession_number":"0001493152-25-028619","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MIRA Pharma awards CEO $242K STI, $915K transaction award, and 62,500 PSUs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Erez Aminov receives $242,258 short-term incentive payout for 2025 performance; additional $80,753 contingent on Phase 1 study completion.","Transaction advisory award of $915,000 approved for negotiating SKNY acquisition; payable in cash, equity, or both at CEO's election.","62,500 performance share units issued and immediately vested upon achievement of first market capitalization milestone under LTI plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127410,"accession_number":"0001493152-25-026445","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MIRA Pharmaceuticals increases ATM offering capacity by $15.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to raise additional $15,241,591 via ATM offering.","Previously sold $7,034,658 of common stock under same agreement with Rodman & Renshaw.","Agreement dated August 12, 2024, amended September 24, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127409,"accession_number":"0001493152-25-019065","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA Pharmaceuticals starts MAD Phase 1 of oral Ketamir-2; selects CIPN for Phase 2a","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiated multiple ascending dose (MAD) portion of Phase 1 trial for oral Ketamir-2 in healthy volunteers.","Selected chemotherapy-induced peripheral neuropathy (CIPN) as lead indication for planned Phase 2a study.","In SAD portion, no serious or dose-limiting adverse events; no clinically significant safety concerns.","Ketamir-2 is a non-scheduled oral analog of ketamine designed for once-daily dosing without psychoactive effects.","Preclinical data showed Ketamir-2 outperformed ketamine, gabapentin, and pregabalin in neuropathic pain models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127408,"accession_number":"0001493152-25-018303","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA Pharmaceuticals sells 1.75M shares at $2.19 each in block deal, raising ~$3.84M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,751,000 shares to institutional investors at avg price of $2.19/share, a 66% premium to prior day's close.","Gross proceeds of ~$3,835,485 before fees; executed via ATM facility through Rodman & Renshaw/StockBlock platform.","No warrants were issued in connection with the block sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127407,"accession_number":"0001493152-25-018141","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA Pharmaceuticals: Oral Mira-55 normalized pain, reduced inflammation, outperforming injected morphine","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oral Mira-55 normalized pain thresholds to baseline and reduced paw edema in formalin-induced chronic pain model, outperforming injected morphine.","Mira-55 showed direct CB2-receptor-mediated anti-inflammatory effect; morphine only partial indirect effect.","First study to directly measure inflammation alongside pain; supports planned IND for chronic inflammatory pain.","Company targeting $70 billion non-opioid pain market with dual-mechanism drug addressing both cause and perception of pain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144198,"accession_number":"0001493152-25-016168","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["1.01","2.01","3.02","9.01"],"status":"ready","headline":"MIRA completes SKNY acquisition, adds three pipeline programs; regains Nasdaq compliance","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of SKNY for restricted MIRA shares; SKNY contributed $5M in marketable securities to MIRA.","Pipeline now includes Ketamir-2 (Phase 1 neuropathic pain), MIRA-55 (oral THC analog), and SKNY-1 (obesity/smoking cessation).","Nasdaq had notified MIRA of stockholders' equity deficiency in April 2025; extension granted to Oct 6, 2025.","After merger closing and ATM sales, MIRA believes it has regained compliance; Nasdaq will continue to monitor.","No specific exchange ratio or deal value disclosed; valuations were independent third-party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144197,"accession_number":"0001493152-25-014393","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA Pharma Phase 1 SAD of Ketamir-2 safe, well tolerated; positive PK","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 SAD study in 32 healthy volunteers (50-600 mg doses) showed no severe or serious adverse events.","Dose-proportional exposure (Cmax, AUC); median Tmax 1-2 h; half-life 2-5 h; metabolite nor-Ketamir half-life 6.5-8.5 h.","Company to initiate MAD portion of Phase 1, followed by Phase 2a trial in neuropathic pain patients.","DEA concluded Ketamir-2 is not a controlled substance under the Controlled Substances Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144196,"accession_number":"0001493152-25-013459","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA announces positive preclinical PTSD data for Ketamir-2 in rat model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ketamir-2 reversed stress-induced avoidance, anxiety, and despair in rats after 5 daily oral doses.","Results from Single Prolonged Stress model showed behavior normalized to non-stressed animal levels.","Ketamir-2 is also in a Phase 1 trial for neuropathic pain with a favorable safety profile to date.","DEA concluded Ketamir-2 is not a controlled substance under the Controlled Substances Act.","A larger follow-on PTSD study in animals is ongoing; results support further development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144195,"accession_number":"0001493152-25-013100","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve SKNY acquisition; combined enterprise value >$60M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["SKNY will contribute $5M in cash or assets to MIRA at closing.","Moore Financial Consulting valued SKNY at $30.5M and MIRA at $30M; combined >$60M.","Directors elected: Erez Aminov, Matthew Whalen, Matthew Del Giudice, Denil Nanji Shekhat, Edward MacPherson.","2022 Omnibus Incentive Plan amended: shares increased from 5M to 8M, option repricing allowed.","Transaction expected to close shortly, subject to customary closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144194,"accession_number":"0001641172-25-024731","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA Pharmaceuticals completes Phase 1 SAD for Ketamir-2; no safety issues, advances to MAD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed SAD phase with 32 participants across 4 cohorts (50-600 mg); no severe adverse effects observed.","Advancing to MAD phase with 3 cohorts (150, 300, 600 mg daily for 5 days) in up to 24 participants.","FDA IND clearance for neuropathic pain already received; U.S. Phase 2a trial planned for Q4 2025.","Safety monitored via C-SSRS, Bowdle VAS, and KSET scales; no clinically significant safety concerns."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144193,"accession_number":"0001641172-25-023110","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA's Ketamir-2 manuscript accepted for publication; shows superior efficacy in neuropathic pain models","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ketamir-2 manuscript accepted in Frontiers in Pharmacology; outperformed ketamine, pregabalin, gabapentin in preclinical models.","Restored sensory function and reversed pain behaviors across genders and species in two validated models.","Global neuropathic pain market: $7.97B (2024) projected to $16.79B by 2034, CAGR 7.73%; North America ~$3.7-3.9B.","Company plans to submit Phase 2a protocol to FDA in Q4 2025, aiming to initiate study by year-end.","Also evaluating Ketamir-2 for depression, anxiety, PTSD, and as a topical formulation for localized pain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144192,"accession_number":"0001641172-25-021356","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA reports preclinical data: topical Ketamir-2 comparable to injected morphine in pain model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Topical Ketamir-2 nearly eliminated paw licking and markedly reduced paw lifting in both acute (0-10 min) and inflammatory (15-60 min) phases.","Comparable efficacy to injected morphine across both pain phases; effects consistent across all 5-min intervals.","Company continues Phase 1 oral Ketamir-2 trial; Phase 2a in neuropathic pain expected later in 2025.","Topical Ketamir-2 is being developed as potential non-opioid treatment for diabetic neuropathy, osteoarthritis, and other pain conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144191,"accession_number":"0001641172-25-021155","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA Pharma receives FDA IND clearance for Ketamir-2, advancing neuropathic pain program","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for Ketamir-2, an oral NMDA antagonist for neuropathic pain, enabling U.S. clinical trials.","Preclinical head-to-head data showed superior efficacy to gabapentin and pregabalin with no ketamine-related neurotoxicity.","Phase 1 single ascending dose portion nearing completion; U.S. Phase 2a efficacy trial planned for Q4 2025.","Acquisition of SKNY Pharmaceuticals on track; SKNY-1 shows efficacy in obesity and nicotine craving models.","MIRA-55 oral cannabinoid analog demonstrated comparable efficacy to morphine in inflammatory pain models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144190,"accession_number":"0001641172-25-018595","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA reports SKNY-1 reverses anxiety behavior in animal model, differentiating from older CB1 drugs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SKNY-1 reversed anxiety-like behavior in zebrafish induced by a CB1 activator, normalizing to control or better levels.","Prior results showed SKNY-1 achieved up to 30% weight loss, reversed nicotine craving, and preserved muscle mass in animal models.","SKNY-1 is designed to avoid CNS side effects that halted earlier CB1 drugs like rimonabant.","Company is preparing for shareholder approval for acquisition of SKNY Pharmaceuticals; expects to start IND-enabling studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144189,"accession_number":"0001641172-25-018247","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA Pharmaceuticals sells 1.55M shares at $1.2981, raising ~$2.0M via ATM facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,550,741 shares to institutional investor in block sales on July 3, 2025.","Average price of $1.2981 per share, a premium to prior day's close.","Gross proceeds of approximately $2.0 million before fees and expenses.","Offering facilitated by Rodman & Renshaw on StockBlock platform; no warrants issued.","Proceeds from at-the-market equity offering facility used for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144188,"accession_number":"0001641172-25-017557","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mira-55 shows morphine-comparable pain relief in animal model; SKNY acquisition clears SEC review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mira-55, a non-psychoactive marijuana analog, matched morphine's pain relief in a formalin-based rodent model without sedation or inflammation.","DEA previously confirmed Mira-55 is not a controlled substance, removing a key regulatory barrier to clinical development.","SEC completed review of merger proxy for SKNY Pharmaceuticals acquisition with no comments, enabling shareholder vote.","SKNY-1, the target therapy, demonstrated 30% body weight reduction without muscle loss and reversal of nicotine cravings in recent studies.","MIRA advancing Mira-55 toward IND submission for inflammatory pain indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162537,"accession_number":"0001641172-25-017046","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA reports SKNY-1 achieves 30% weight loss and reverses cravings in zebrafish obesity model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SKNY-1 reduced body weight by ~30% in six days; treated animals weighed ~10% less than healthy controls.","Liver fat buildup reversed to healthy levels; cholesterol (LDL/HDL) normalized without disrupting metabolic balance.","Obese animals ate 2-3x more high-calorie food; SKNY-1 dose-dependently reduced compulsive eating and food-seeking.","Nicotine craving and seeking behavior significantly reduced; high-dose group matched healthy animal behavior.","Leptin and ghrelin normalized; lower-dose SKNY-1 reduced elevated brain dopamine linked to reward cravings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162536,"accession_number":"0001641172-25-016285","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA reports preclinical data for SKNY-1: biased CB1 modulation, CB2 activity, selective MAO-B inhibition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SKNY-1 shows biased CB1 antagonism: blocks β-arrestin (cravings) but spares G-protein (mood stability), unlike rimonabant.","Partial agonist at CB2 receptor, targeting metabolic regulation and inflammation for obesity comorbidities.","Selective MAO-B inhibition; no MAO-A or D1/D2/D3 dopamine receptor activity, supporting CNS safety.","Data from Eurofins in vitro studies; in vivo animal models for weight loss and nicotine addiction are being finalized.","Acquisition of SKNY by MIRA remains subject to regulatory and shareholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162535,"accession_number":"0001641172-25-015401","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA Pharma announces Ketamir-2 publication, Phase 1 progress, SKNY acquisition update","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ketamir-2 accepted for publication in Frontiers in Pharmacology; highlights selective NMDA antagonism, no hyperlocomotion, improved oral bioavailability.","Phase 1 trial advancing as planned with dose escalation ongoing; no reported safety concerns.","Phase 2a trial in neuropathic pain expected to initiate by year-end 2025, pending regulatory clearance.","Acquisition of SKNY Pharmaceuticals (including SKNY-1 for obesity/smoking cessation) progressing; SEC filings submitted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162534,"accession_number":"0001641172-25-012603","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA updates on Ketamir-2 Phase 1 progress, plans Phase IIa in neuropathic pain by end of 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Participating in BIO International Convention June 16-19, 2025 for partnering and licensing discussions.","Second dosing cohort of Ketamir-2 Phase 1 completed; company preparing to initiate third cohort.","Phase IIa trial in neuropathic pain expected to start by end of 2025.","Preclinical studies ongoing for PTSD and topical formulation for localized inflammatory pain.","Finalizing regulatory filings for SKNY acquisition; SKNY-1 targets smoking cessation and obesity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162533,"accession_number":"0001641172-25-011936","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["1.01","5.02","3.02","9.01"],"status":"ready","headline":"MIRA Pharmaceuticals appoints Alan Weichselbaum as CFO; prior CFO Michelle Yanez resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Michelle Yanez resigned effective May 16, 2025; mutual separation not based on any disagreement.","Alan Weichselbaum appointed CFO effective May 15, 2025; also CFO of Telomir Pharma and CEO of The Wexus Group.","Employment agreement: $60,000 annual salary (part-time, 20 hrs/week), 75,000 stock options vesting over 12 months.","Weichselbaum brings over 30 years of corporate finance experience; previously at Philip Morris and Price Waterhouse."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162532,"accession_number":"0001641172-25-009155","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA Pharmaceuticals to acquire SKNY; combined enterprise value over $60M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Board unanimously approved definitive agreement to acquire SKNY on April 30, 2025.","Third-party valuation assigned SKNY enterprise value of ~$30.5M; MIRA ~$30M.","SKNY to contribute $5M in assets or cash at closing with no contingencies.","Combined enterprise value exceeds $60M, creating a broader platform targeting obesity and nicotine dependence.","MIRA preparing to file proxy statement to seek shareholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162531,"accession_number":"0001641172-25-008748","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA Pharma reports no brain toxicity in FDA-required Ketamir-2 study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ketamir-2 showed no mortality, adverse signs, or brain lesions in rats at high doses.","Positive control MK-801 caused vacuolation and neuronal necrosis (Olney lesions).","Results to be submitted to FDA as part of ongoing regulatory communications.","Study supports Ketamir-2's safety profile versus ketamine-linked neurotoxicity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162530,"accession_number":"0001641172-25-005772","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA Pharmaceuticals' topical Ketamir-2 shows successful drug release in IVRT study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Topical Ketamir-2 demonstrated dose-proportional release in in vitro release testing, enabling non-opioid pain therapy.","Preclinical efficacy studies in inflammatory and neuropathic pain models to begin shortly.","Company evaluating Fast Track designation with FDA; U.S. topical pain relief market projected >$11.5B in 2025.","Oral Ketamir-2 in Phase 1 trial; Phase 2a for diabetic neuropathy expected later in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162529,"accession_number":"0001641172-25-004971","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA Pharma: Ketamir-2 shows positive preclinical results in diabetic neuropathy rat model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ketamir-2 significantly reduced neuropathic pain in a rat model of type 2 diabetes (high-fat diet + STZ).","Some treated animals returned to pre-diabetic baseline sensitivity, indicating full symptom reversal.","Results confirm oral bioavailability and non-dissociative profile, supporting ongoing Phase I trial in healthy volunteers.","Company plans to initiate Phase IIa trial in diabetic neuropathy patients by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162528,"accession_number":"0001641172-25-003889","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"MIRA receives Nasdaq minimum equity deficiency notice; equity $2.2M vs $2.5M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity $2,199,750 as of Dec 31, 2024, below Nasdaq's $2.5M minimum requirement under Rule 5550(b)(1).","Company has 45 days to submit a compliance plan by May 23, 2025; Nasdaq may grant up to 180-day extension.","Plans to complete SKNY Pharmaceuticals acquisition with $5M capital infusion to boost equity.","Also in discussions with strategic investors to strengthen capital position; trading continues uninterrupted.","Phase 1 trial of Ketamir-2 for neuropathic pain ongoing; first subject dosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":162527,"accession_number":"0001641172-25-001987","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2 for neuropathic pain","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial of oral ketamine analog Ketamir-2 for neuropathic pain; 56 healthy volunteers in SAD/MAD cohorts.","Preclinical data showed superior efficacy vs. pregabalin and gabapentin in validated neuropathic pain models.","Study completion expected Q4 2025; Phase 2a in diabetic neuropathic pain to start by year-end 2025.","First human efficacy data anticipated in first half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180540,"accession_number":"0001641172-25-000199","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MIRA Pharma to acquire SKNY in stock-for-stock deal; adds weight loss drug SKNY-1","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["SKNY contributes $5M in cash/assets at closing, no contingencies.","Exchange ratio determined by independent valuation; subject to SKNY valuation >= MIRA market value.","90-day mutual due diligence period; definitive agreement required within 180 days after.","No SKNY board, executives, or employees will retain roles post-closing.","SKNY stockholders subject to 6-month lock-up on MIRA shares received."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180539,"accession_number":"0001493152-25-010140","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mira Pharmaceuticals develops topical Ketamir-2 for localized pain; preclinical study underway","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Topical Ketamir-2 designed for slow release, enabling targeted pain relief with minimal systemic exposure.","Preclinical study assessing efficacy of topical formulation against inflammatory pain is ongoing.","Phase 1 oral trial for Ketamir-2 continues; Phase 2a in diabetic neuropathy planned by year-end 2025.","First human efficacy data from Phase 2a expected in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180538,"accession_number":"0001493152-25-008977","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA Pharma receives Israeli MoH approval to start Phase 1 trial for Ketamir-2 in neuropathic pain","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approval from Israeli Ministry of Health and IRB to initiate Phase 1 trial for Ketamir-2, an oral ketamine analog.","Randomized, double-blind, placebo-controlled study evaluating safety, tolerability, and PK in healthy volunteers at Hadassah Medical Center.","Subject recruitment begins Q1 2025; Phase 1 expected to conclude Q4 2025, followed by Phase 2a in neuropathic pain patients by year-end.","Awaiting neurotoxicity study results from FDA, expected Q2 2025, to enable IND and U.S. patient dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197351,"accession_number":"0001493152-24-051091","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"MIRA Pharmaceuticals replaces auditor Cherry Bekaert with Salberg; material weaknesses cited","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cherry Bekaert resigned as auditor effective Dec 16, 2024; no disagreements but noted material weaknesses in internal controls for 2022 and 2023.","Salberg & Company P.A. engaged as new independent auditor for fiscal year ending Dec 31, 2024, effective Dec 18.","Cherry Bekaert's prior reports included a going concern explanatory paragraph.","No disagreements or reportable events other than the material weaknesses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197350,"accession_number":"0001493152-24-050695","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA submits IND for Ketamir-2 (neuropathic pain) to FDA; Phase I expected Q1 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["IND submitted to FDA on Dec 19, 2024 for Ketamir-2, a novel oral ketamine analog.","Phase I clinical trials expected to start Q1 2025; Phase IIa planned for late 2025.","Preclinical data showed full pain reversal with no adverse safety findings.","Ketamir-2 targets unmet needs in neurological disorders and neuropathic pain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197349,"accession_number":"0001493152-24-049377","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mira Pharma completes Ketamir-2 GLP safety program; no adverse findings, IND submission by year-end 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Successful completion of GLP preclinical safety program for Ketamir-2; no adverse findings across cardiovascular, CNS, respiratory, and toxicology studies.","Key results: cardiovascular safety in dogs, CNS assessment in rats (transient high-dose effects), 14-day dog tox up to 200 mg/kg, Ames test non-mutagenic.","Plan to submit IND by end of 2024; Phase I trial start Q1 2025 for safety, tolerability, PK/PD, and pain evaluation.","Early Phase I data expected Q2 2025; focus on neuropathic pain and psychosis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197348,"accession_number":"0001493152-24-047146","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Mira Pharmaceuticals appoints Matthew Pratt Whalen to board, replacing Michael Jerman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Jerman resigned as director and Audit Committee Chair effective Nov 18, 2024, not due to any disagreement.","Matthew Pratt Whalen appointed as director and Audit Committee Chair effective same day.","Whalen is a CPA with over 20 years experience, currently CFO of Power Digital Marketing since May 2021.","Whalen also serves as director on the board of Telmoir Pharmaceuticals (NASDAQ: TELO) since August 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197347,"accession_number":"0001493152-24-046812","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA Pharmaceuticals selects CHDR for Phase I/IIa trial of Ketamir-2; recruitment starts Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trial site: The Centre for Human Drug Research (CHDR) in Leiden, Netherlands.","Phase I in healthy subjects: initial safety/efficacy results expected H2 2025.","Phase IIa planned Q4 2025 in diabetic neuropathy patients; efficacy results in H1 2026.","Will use CHDR's PainCart® technology for early pain response measurement.","Psychoactivity assessed separately; trial leverages unique early-efficacy capability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197346,"accession_number":"0001493152-24-042511","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mira Pharmaceuticals' Ketamir-2 shows 60% greater efficacy than gabapentin in preclinical neuropathy study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ketamir-2 demonstrated 60% greater efficacy than FDA-approved gabapentin in a preclinical model of chemotherapy-induced neuropathic pain.","Company plans additional preclinical studies targeting diabetic neuropathy and PTSD.","Exploring government funding opportunities to support the development program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197345,"accession_number":"0001493152-24-041702","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mira Pharma reports Ketamir-2 beats Gabapentin and Pregabalin in preclinical neuropathic pain study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ketamir-2 demonstrated significantly greater efficacy than FDA-approved Gabapentin (Neurontin) and Pregabalin (Lyrica) in preclinical neuropathic pain models.","IND application submission remains on track for end of 2024; Phase I trials expected to begin Q1 2025; Phase II by late 2025.","Exploring government funding opportunities to support planned PTSD clinical trials.","Additional preclinical studies focused on chemotherapy-induced and diabetic neuropathy are actively underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213589,"accession_number":"0001493152-24-036057","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MIRA Pharmaceuticals announces 2024 annual meeting results; all proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected; each received over 6.6M votes (70.4% of votes cast).","Ratification of Cherry Bekaert LLP as auditor for FY2024 approved with 9.4M votes for (99.9%).","Amendment to 2022 Omnibus Incentive Plan to increase available shares approved with 6.57M votes for (84.6% of votes cast).","Adjournment proposal withdrawn after sufficient votes obtained for proposals 1 and 3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213588,"accession_number":"0001493152-24-035625","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mira Pharma selects neuropathic pain for Ketamir-2, submits pre-IND request to FDA","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Selected neuropathic pain as primary indication for oral ketamine analog Ketamir-2.","Submitted pre-IND meeting request to FDA; meeting expected October 2024.","Plans to begin human trials in Q1 2025 following IND submission.","No financial details or trial data disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":213587,"accession_number":"0001493152-24-033718","cik":1904286,"company_name":"MIRA PHARMACEUTICALS, INC.","ticker":"MIRA","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MIRA Pharma reports 100% pain signal reversal with oral Ketamir-2 in rat neuropathic pain model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Low oral doses of Ketamir-2 reversed neuropathic pain for 14-22 days in nerve-ligation rat model.","Highest dose achieved complete normalization of pain threshold, a 100% reversal of pain signal.","Oral ketamine under same conditions showed no significant pain relief, highlighting Ketamir-2's superiority.","Company plans further clinical development for Ketamir-2 as a transformative neuropathic pain treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43913079.57142856,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-08-23T23:59:59+00:00|213587"}